Daiwa Securities Group’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-121
| Closed | -$1K | – | 1355 |
|
|
2025
Q2 | $1K | Hold |
121
| – | – | ﹤0.01% | 1266 |
|
|
2025
Q1 | $1K | Hold |
121
| – | – | ﹤0.01% | 1230 |
|
|
2024
Q4 | $1K | Hold |
121
| – | – | ﹤0.01% | 1254 |
|
|
2024
Q3 | $1K | Hold |
121
| – | – | ﹤0.01% | 1250 |
|
|
2024
Q2 | $2K | Hold |
121
| – | – | ﹤0.01% | 1251 |
|
|
2024
Q1 | $2K | Hold |
121
| – | – | ﹤0.01% | 1269 |
|
|
2023
Q4 | $1K | Hold |
121
| – | – | ﹤0.01% | 1299 |
|
|
2023
Q3 | $1K | Hold |
121
| – | – | ﹤0.01% | 1258 |
|
|
2023
Q2 | $2K | Hold |
121
| – | – | ﹤0.01% | 1235 |
|
|
2023
Q1 | $2K | Hold |
121
| – | – | ﹤0.01% | 1219 |
|
|
2022
Q4 | $2K | Hold |
121
| – | – | ﹤0.01% | 1227 |
|
|
2022
Q3 | $2K | Hold |
121
| – | – | ﹤0.01% | 1233 |
|
|
2022
Q2 | $2K | Hold |
121
| – | – | ﹤0.01% | 1243 |
|
|
2022
Q1 | $4K | Hold |
121
| – | – | ﹤0.01% | 1194 |
|
|
2021
Q4 | $6K | Hold |
121
| – | – | ﹤0.01% | 1183 |
|
|
2021
Q3 | $3K | Buy |
121
+55
| +83% | +$1.44K | ﹤0.01% | 1215 |
|
|
2021
Q2 | $2K | Hold |
66
| – | – | ﹤0.01% | 1141 |
|
|
2021
Q1 | $2K | Hold |
66
| – | – | ﹤0.01% | 1145 |
|
|
2020
Q4 | $2K | Buy |
+66
| New | +$1.75K | ﹤0.01% | 1123 |
|
Other funds holding ITOS
Daiwa Securities Group's ITOS Position: Q3 2025 in Review
Daiwa Securities Group sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 121 shares — an estimated $1K sold.
Daiwa Securities Group first reported a position in ITOS in Q4 2020 and held it in 19 quarters. The position peaked at $6K in Q4 2021. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Daiwa Securities Group reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Daiwa Securities Group sold 121 iTeos Therapeutics shares in Q3 2025, an estimated $1K.
- Daiwa Securities Group first reported a position in iTeos Therapeutics in Q4 2020 and held it in 19 quarters.
- Daiwa Securities Group's iTeos Therapeutics position peaked at $6K in Q4 2021.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Daiwa Securities Group's 13F filing for Q3 2025, filed 14 Nov 2025.